Heterogeneous nuclear ribonucleoprotein A2/B1, a key regulator of myocardial fibrosis

Ji-Hoon Jeong; Kayode Abidemi John; Juyeong Hong; Ji Hoon Lee

doi:10.1002/ctd2.319

Clinical and Translational Discovery ›› 2024, Vol. 4 ›› Issue (3) :e319 DOI: 10.1002/ctd2.319

COMMENTARY

Heterogeneous nuclear ribonucleoprotein A2/B1, a key regulator of myocardial fibrosis

Author information +

History +

PDF

Keywords

miRNA / myocardial fibrosis / RNA m ⁶A methylation

Cite this article

Download citation ▾

Ji-Hoon Jeong, Kayode Abidemi John, Juyeong Hong, Ji Hoon Lee. Heterogeneous nuclear ribonucleoprotein A2/B1, a key regulator of myocardial fibrosis. Clinical and Translational Discovery, 2024, 4(3): e319 DOI:10.1002/ctd2.319

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Goldsmith EC, Bradshaw AD, Zile MR, Spinale FG. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014;70:92-99.

[2]	Ieda M, Tsuchihashi T, Ivey KN, et al. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell. 2009;16:233-244.

[3]	Tallquist MD, Molkentin JD. Redefining the identity of cardiac fibroblasts. Nat Rev Cardiol. 2017;14:484-491.

[4]	Yokota T, McCourt J, Ma F, et al. Type V collagen in scar tissue regulates the size of scar after heart injury. Cell. 2020;182:545-562. e523.

[5]	Alarcon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. hnRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell. 2015;162:1299-1308.

[6]	Wang X, Wu Y, Guo R, Zhao L, Yan J, Gao C. Comprehensive analysis of N6-Methyladenosine RNA methylation regulators in the diagnosis and subtype classification of acute myocardial infarction. J Immunol Res. 2022;2022:5173761.

[7]	Li X, Shi S, Li Z, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 promotes myocardial fibrosis by regulating the miR-221-3p/FOXO4-mediated inflammation. Clin Transl Med. 2024;14:e1616.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.